Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Chaput G, Sumar N. Endocrine therapies for breast and prostate cancers. Can Family Physician. 2022;68(4):271–6. https://doi.org/10.46747/cfp.6804271.

Article  Google Scholar 

Rugo HS, Vidula N, Ma C, Rugo MA. Improving response to hormone therapy in breast cancer: new targets, new therapeutic options understanding the biology of hormone receptors and potential mechanisms of resistance mechanisms of action of estrogen receptors, vol. 12. 2016.

Lumachi F. Current medical treatment of estrogen receptor-positive breast cancer. World J Biol Chem. 2015;6(3):231.

Article  PubMed  PubMed Central  Google Scholar 

Ruddy KJ, O’Neill A, Miller KD, Schneider BP, Baker E, Sparano JA, et al. Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103. Breast Cancer Res Treat. 2014;144(3):591–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berkowitz MJ, Thompson CK, Zibecchi LT, Lee MK, Streja E, Berkowitz JS, et al. How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support. J Cancer Surv. 2021;15(1):29–39.

Article  Google Scholar 

Kadakia KC, Snyder CF, Kidwell KM, Seewald NJ, Flockhart DA, Skaar TC, et al. Patient-reported outcomes and early discontinuation in aromatase inhibitor-treated postmenopausal women with early stage breast cancer. Oncologist. 2016;21(5):539–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wróbel TM, Bartuzi D, Kaczor AA. Secondary binding site of CYP17A1 in enhanced sampling simulations. J Chem Inf Model. 2024.

Sasano H, Dowsett M, Pasqualini JR. Journal of steroid biochemistry and molecular biology: preface. J Steroid Biochem Mol Biol. 2003.

Capper CP, Larios JM, Sikora MJ, Johnson MD, Rae JM. The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer. Breast Cancer Res Treat. 2016;157(1):23–30.

Article  CAS  PubMed  Google Scholar 

Zhang Y, Li H, Zhang J, Zhao C, Lu S, Qiao J, et al. The combinatory effects of natural products and chemotherapy drugs and their mechanisms in breast cancer treatment, vol. 19, Phytochemistry reviews. Springer, Berlin 2020;1179–1197.

Rahman S, Husen A. Trigonella foenum-graecum L. A useful medicinal plant for diabetes and other. 2023.

Mao QQ, Xu XY, Cao SY, Gan RY, Corke H, Beta T, et al. Bioactive compounds and bioactivities of ginger (zingiber officinale roscoe). Vol. 8, Foods. MDPI. 2019.

Baliga MS, Jimmy R, Thilakchand KR, Sunitha V, Bhat NR, Saldanha E, et al. Ocimum Sanctum L (Holy Basil or Tulsi) and its phytochemicals in the prevention and treatment of cancer. In: Nutrition and cancer 2013;26–35.

Cohen MM. Tulsi—Ocimum sanctum: A herb for all reasons. Vol. 5, Journal of Ayurveda and Integrative Medicine. Medknow Publications; 2014;251–9.

Bouhenni H, Doukani K, Hanganu D, Olah NK, Sekeroǧlu N, Gezici S, et al. Comparative analysis on bioactive compounds and antioxidant activity of Algerian fenugreek (Trigonella foenum-graecum L.) and Syrian cumin (Cuminum cyminum L.) seeds. Herba Polonica. 2021;67(1):18–34.

Gupta K, Gautre P, Biharee A, Singh Y, Patil UK, Kumar S, et al. Exploring the potential of essential oil from Plectranthus amboinicus leaves against breast cancer: in vitro and in silico analysis. Med Oncol. 2024;41(4):81.

Article  CAS  PubMed  Google Scholar 

Kalirajan R, Sankar S, Jubie S, Gowramma B. Molecular docking studies and in-silico ADMET screening of some novel oxazine substituted 9-anilinoacridines as topoisomerase II inhibitors. Indian J Pharm Educ Res. 2017;51(1):110–5.

Article  CAS  Google Scholar 

Abdi SAH, Ali A, Sayed SF, Ahsan MJ, Tahir A, Ahmad W, et al. Morusflavone, a new therapeutic candidate for prostate cancer by cyp17a1 inhibition: exhibited by molecular docking and dynamics simulation. Plants. 2021;10(9).

Dey A, Belayet Hasan Limon M, Thosif Raza M. Virtual screening and identification of plant-based novel inhibitors of CYP17A1 for the treatment of Polycystic Ovarian Syndrome (PCOS) [Internet]. 2024. https://ssrn.com/abstract=4878157

Hajji H, Tabti K, En-Nahli F, Bouamrane S, Lakhlifi T, Ajana MA, et al. In silico investigation on the beneficial effects of medicinal plants on diabetes and obesity: molecular docking, molecular dynamic simulations, and ADMET studies. 2021. https://biointerfaceresearch.com/

Senthilraja P, Kathiresan K. In vitro cytotoxicity MTT assay in vero, HepG2 and MCF-7 cell lines study of marine yeast. J Appl Pharm Sci. 2015;5(3):80–4.

Article  Google Scholar 

Hengartner MO. The biochemistry of apoptosis. Vol. 407, Nature. 2000;770–6.

Xiao F, Yang M, Xu Y, Vongsangnak W. Comparisons of prostate cancer inhibitors abiraterone and TOK-001 binding with CYP17A1 through molecular dynamics. Comput Struct Biotechnol J. 2015;13:520–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Estrada DF, Skinner AL, Laurence JS, Scott EE. Human cytochrome P450 17A1 conformational selection: Modulation by ligand and cytochrome b5. J Biol Chem. 2014;289(20):14310–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fernández-Cancio M, Camats N, Flück CE, Zalewski A, Dick B, Frey BM, et al. Mechanism of the dual activities of human CYP17A1 and binding to anti-prostate cancer drug abiraterone revealed by a novel V366M mutation causing 17,20 lyase deficiency. Pharmaceuticals. 2018;11(2).

Rampogu S, Lee G, Park JS, Lee KW, Kim MO. Molecular docking and molecular dynamics simulations discover curcumin analogue as a plausible dual inhibitor for SARS-CoV-2. Int J Mol Sci. 2022;23(3).

Tajiani F, Ahmadi S, Lotfi S, Kumar P, Almasirad A. In-silico activity prediction and docking studies of some flavonol derivatives as anti-prostate cancer agents based on Monte Carlo optimization. BMC Chem. 2023;17(1).

Devore NM, Scott EE. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. Vol. 482, Nature. 2012;116–9.

Hashemzadeh H, Javadi H, Darvishi MH. Study of structural stability and formation mechanisms in DSPC and DPSM liposomes: a coarse-grained molecular dynamics simulation. Sci Rep. 2020;10(1).

Pandya A, Zhang C, Barata TS, Brocchini S, Howard MJ, Zloh M, et al. Molecular dynamics simulations reveal how competing protein-surface interactions for glycine, citrate, and water modulate stability in antibody fragment formulations. Mol Pharm. 2024.

Omoboyowa DA, Balogun TA, Saibu OA, Chukwudozie OS, Alausa A, Olubode SO, et al. Structure-based discovery of selective CYP17A1inhibitors for Castration-resistant prostate cancer treatment. Biol Methods Protoc. 2022;7(1).

Khan T, Dixit S, Ahmad R, Raza S, Azad I, Joshi S, et al. Molecular docking, PASS analysis, bioactivity score prediction, synthesis, characterization and biological activity evaluation of a functionalized 2-butanone thiosemicarbazone ligand and its complexes. J Chem Biol. 2017;10(3):91–104.

Article  PubMed  PubMed Central  Google Scholar 

Martin YC. A bioavailability score. J Med Chem. 2005;48(9):3164–70.

Article  CAS  PubMed  Google Scholar 

Mu J, Song J, Li R, Xue T, Wang D, Yu J. Isovitexin prevents DSS-induced colitis through inhibiting inflammation and preserving intestinal barrier integrity through activating AhR. Chem Biol Interact. 2023;382:110583.

Article  CAS  PubMed  Google Scholar 

Ibrahim MT, Uzairu A, Uba S, Shallangwa GA. Quantitative structure-activity relationship, molecular docking, drug-likeness, and pharmacokinetic studies of some non-small cell lung cancer therapeutic agents. Beni Suef Univ J Basic Appl Sci. 2020;9(1).

Crespo B, Illera JC, Silvan G, Lopez-Plaza P, Herrera de la Muela M, de la Puente Yagüe M, et al. Androgen and estrogen β receptor expression enhances efficacy of antihormonal treatments in triple-negative breast cancer cell lines. Int J Mol Sci. 2024;25(3).

Çilesiz Y, Çevik Ö. Anticancer effect of the letrozole-quercetin combination mediated by FOXOs and estrogen receptors in breast cancer cells. J Res Pharm. 2021;25(4):479–89.

Google Scholar 

Gu G, Tian L, Herzog SK, Rechoum Y, Gelsomino L, Gao M, et al. Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021;40(5):997–1011.

Article  CAS  PubMed  Google Scholar 

Hu LX, Du YY, Zhang Y, Pan YY. Synergistic effects of exemestane and aspirin on MCF-7 human breast cancer cells. Asian Pac J Cancer Prev. 2012;13(11):5903–8.

Article  PubMed  Google Scholar 

Shen Y, Du Y, Zhang Y, Pan Y. Synergistic effects of combined treatment with simvastatin and exemestane on MCF-7 human breast cancer cells. Mol Med Rep. 2015;12(1):456–62.

Article  CAS  PubMed  Google Scholar 

Thiantanawat A, Long BJ, Brodie AM. Cancer Res Downloaded from [Internet]. Vol. 63, CANCER RESEARCH. 2003. http://cancerres.aacrjournals.org/content/63/22/8037.

Conforti F, Menichini F, Rigano D, Senatore F. Antiproliferative activity on human cancer cell lines after treatment with polyphenolic compounds isolated from Iris pseudopumila flowers and rhizomes. Zeitschrift für Naturforschung C. 2009;64(7–8):490–4.

Article  CAS  Google Scholar 

Li J, Shang L, Zhou F, Wang S, Liu N, Zhou M, et al. Herba Patriniae and its component Isovitexin show anti-colorectal cancer effects by inducing apoptosis and cell-cycle arrest via p53 activation. Biomed Pharmacother. 2023;1:168.

CAS  Google Scholar 

Lv SX, Qiao X. Isovitexin (IV) induces apoptosis and autophagy in liver cancer cells through endoplasmic reticulum stress. Biochem Biophys Res Commun. 2018;496(4):1047–54.

Article  CAS  PubMed  Google Scholar 

Ganesan K, Xu B. Molecular targets of vitexin and isovitexin in cancer therapy: a critical review. Ann N Y Acad Sci. 2017;1401:102–13.

Article  CAS  PubMed  Google Scholar